Fludarabine
Myxoid/Round Cell Liposarcoma
Sotio Biotech Inc.Small moleculePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Myxoid/Round Cell Liposarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Sotio Biotech Inc. | Phase 1/2 | CCC |
gpc3-car-t cells Sotio Biotech Inc. | Phase 1/2 | CCC |
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells USWM CT, LLC | Phase 1 | CC |
Ny-Eso-1 Tcr Redirected Autologous T Cell Product University of Pennsylvania | Phase 1 | CC |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →